Drug Trial Radar · NCT01420783
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Last checked: Nov 21, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Oct 2011
Primary completion
Nov 2012
Study completion May 2014
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: * Dose Ranging Phase: To evaluate the efficacy of daily oral doses of 100, 200, and 400 mg SAR302503 in patients with PV and ET who are resistant or intolerant to hydroxyurea (per European LeukemiaNet criteria) for : * Inducing absence of phlebotomy and a hematocrit below 45% for a minimum of 3 months in patients with polycythemia vera, and * Reduction of platelet count to ≤400 x 10x9/L for a minimum of 3 months in patients with essential thrombocythemia. * PV Dose Expansion Phase and ET Dose Ranging Phase (only 600 mg dose group): To evaluate the efficacy of daily oral SAR302503 in patients with PV and ET who are resistant or intolerant to hydroxyurea (per European LeukemiaNet criteria) for: * Inducing absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit in patients with PV, and * Reduction of platelet count to ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit in patients with ET. Secondary Objectives: * To evaluate the safety of SAR302503. * To evaluate the efficacy of SAR302503 in patients with PV who are resistant or intolerant to hydroxyurea for inducing absence of phlebotomy eligibility. * To evaluate the efficacy of SAR302503 in patients with ET who are resistant or intolerant to hydroxyurea for reduction of platelet counts. * To evaluate the efficacy of SAR302503 in inducing complete and partial responses beginning at Day 1 of Cycle 6 visit through Cycle 8. * To evaluate splenic response as measured by spleen volume using MRI or CT. * To evaluate the pharmacokinetics of SAR302503 after single and repeat doses. * To evaluate the pharmacodynamics of SAR302503 as measured by changes in JAK2V617F allele burden in patients with JAK2V617F mutation, and STAT3 phosphorylation inhibition. * To measure improvement in baseline myeloproliferative neoplasm (MPN)-associated symptoms, as well as overall impact on quality of life. * To measure generic health-related quality of life and utility value using the EuroQol Group (EQ-5DTM) questionnaire.
Conditions
- Hematopoietic Neoplasm
Interventions
SAR302503Drug
Pharmaceutical form:capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Ranging Phase: Proportion of PV patients with absence of phlebotomy and hematocrit below 45% and proportion of ET patients with a platelet count ≤ 400 x 10x9/L for a minimum of 3 months during the first 8 cycles of therapy.Time frame: 2 years
- PV Dose Expansion Phase: Proportion of PV patients with absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.Time frame: 2 years
- ET Dose Ranging Phase (only 600 mg dose group): Proportion of ET patients with a platelet count ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.Time frame: 2 years
Locations
35 sites in 9 countries. Site status is shown where the registry gives one.
Investigational Site Number 840008
Scottsdale, Arizona
Investigational Site Number 840004
La Jolla, California
Investigational Site Number 840005
Los Angeles, California
Investigational Site Number 840011
Palo Alto, California
Investigational Site Number 840010
Ann Arbor, Michigan
Investigational Site Number 840007
Rochester, Minnesota
Investigational Site Number 840003
St Louis, Missouri
Investigational Site Number 840001
Houston, Texas
Investigational Site Number 036001
Clayton, Australia
Investigational Site Number 036002
Kingswood, Australia
Investigational Site Number 036004
Kogarah, Australia
Investigational Site Number 036003
Randwick, Australia
Investigational Site Number 124002
Montreal, Canada
Investigational Site Number 124003
Toronto, Canada
Investigational Site Number 124001
Vancouver, Canada
Investigational Site Number 250004
Brest, France
Investigational Site Number 250003
Marseille, France
Investigational Site Number 250001
Paris, France
Investigational Site Number 276004
Frankfurt am Main, Germany
Investigational Site Number 276003
Mannheim, Germany
Investigational Site Number 380003
Bologna, Italy
Investigational Site Number 380001
Florence, Italy
Investigational Site Number 380004
Orbassano, Italy
Investigational Site Number 410001
Seongnam, South Korea
Investigational Site Number 410003
Seoul, South Korea
Investigational Site Number 410004
Seoul, South Korea
Investigational Site Number 410002
Seoul, South Korea
Investigational Site Number 724004
Badalona, Spain
Investigational Site Number 724001
Barcelona, Spain
Investigational Site Number 724003
Madrid, Spain
Investigational Site Number 724002
Valencia, Spain
Investigational Site Number 826001
Belfast, United Kingdom
Investigational Site Number 826006
Birmingham, United Kingdom
Investigational Site Number 826003
London, United Kingdom
Investigational Site Number 826004
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.